WHO ICTRP trial
Methylphenidate and atomoxetine in attention deficit hyperactivity disorder
IRCT20110802007202N15 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT20110802007202N15 |
|---|---|
| Public title | Methylphenidate and atomoxetine in attention deficit hyperactivity disorder |
| Scientific title | Comparison of the effectiveness of methylphenidate and atomoxetine in the treatment of attention deficit hyperactivity disorder in adult patients |
| Primary sponsor | Tehran University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | 3 |
| Countries | Iran (Islamic Republic of) |
| Conditions | Attention deficit hyperactivity disorder in adults. Attention-deficit hyperactivity disorder, unspecified type |
| Interventions | Intervention 1: Intervention group 1: Pharmacotherapy with methylphenidate 10 milligram immediate release tablets ( Ritalin) manufactured by Novartis pharmaceutical industry in Switzerland. The medicine's dosage is determined by… |
| Registration date | Nov 8, 2018 |
| Target size | 36 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: